Study title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study of intravenous Sidenafil in the treatment of children, aged 0 to 17 with pulmonary hypertension.
Type of medicine: Centrally authorised medicines | |||||
Therapeutic area: Cardiovascular Diseases | |||||
Brands: Please see report, Please see report, Please see report | |||||
MAH holders: Please see report, Please see report | |||||
Assessment: | |||||
Active substance: sildenafil | |||||
ATC code: G04BE03 | |||||
Document link: A1481134 EMA Pediatrics Web Synopsis.pdf | |||||
Document date: 2013-10-01 | |||||
Study number: A1481134 | |||||
EudraCT number: | |||||
Scope of study: CLINICAL | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | Y | Y | Y | Y |